OVID
Ovid Therapeutics Inc.
Price Chart
Latest Quote
$2.25
-0.02 (-0.88%)
Current Price
| Previous Close | $2.27 |
| Open | $2.32 |
| Day High | $2.37 |
| Day Low | $2.21 |
| Volume | 2,245,846 |
Stock Information
| Shares Outstanding | 186.64M |
| Total Debt | $13.07M |
| Cash Equivalents | $155.52M |
| Revenue | $7.12M |
| Net Income | $-24.07M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $419.94M |
| EPS (TTM) | $-0.21 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $277.49M |
| Sales | $7.12M |
| Income | $-24.07M |
| Book/sh | $1.19 |
| Cash/sh | $0.83 |
| Employees | 23 |
Financial Ratios
| Quick Ratio | 9.88 |
| Current Ratio | 10.17 |
| Debt/Eq | 6.59 |
Returns & Margins
| ROA | -19.66% |
| ROE | -18.77% |
| Gross Margin | 100.00% |
| Operating Margin | -678.67% |
Ownership
| Insider Ownership | 6.98% |
| Institutional Ownership | 61.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.98 |
| P/S | 58.96 |
| P/B | 1.90 |
Analyst Data
| Recommendation | none |
| Target Price | $5.47 |
Technical Indicators
| SMA20 | $2.41 |
| SMA50 | $2.60 |
| SMA200 | $1.88 |
| RSI | 36.04 |
| ATR | 0.1671 |
| Shares Float | 152.44M |
| Short Float | 6.57% |
| Short Ratio | 6.06 |
| Volatility | 0.18 |
| Rel Volume | 1.01 |
Performance History
| Week | -2.17% |
| Month | -5.86% |
| Quarter | -14.12% |
| 6 Months | +52.03% |
| YTD | +27.84% |
| Year | +660.14% |
| 3 Years | -41.25% |
| 5 Years | -49.44% |
| 10 Years | -81.63% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $2.25 | 2,567,900 |
| 2026-06-18 | $2.27 | 15,348,100 |
| 2026-06-17 | $2.42 | 3,863,500 |
| 2026-06-16 | $2.36 | 2,363,300 |
| 2026-06-15 | $2.26 | 1,843,200 |
| 2026-06-12 | $2.30 | 2,061,900 |
| 2026-06-11 | $2.21 | 2,883,300 |
| 2026-06-10 | $2.28 | 1,607,500 |
| 2026-06-09 | $2.42 | 1,483,600 |
| 2026-06-08 | $2.36 | 1,471,300 |
| 2026-06-05 | $2.40 | 1,410,900 |
| 2026-06-04 | $2.48 | 1,276,300 |
| 2026-06-03 | $2.39 | 2,204,600 |
| 2026-06-02 | $2.40 | 1,416,900 |
| 2026-06-01 | $2.56 | 1,980,900 |
| 2026-05-29 | $2.73 | 1,670,500 |
| 2026-05-28 | $2.64 | 1,788,900 |
| 2026-05-27 | $2.54 | 962,000 |
| 2026-05-26 | $2.45 | 1,091,700 |
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
đ° Latest News
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely
Simply Wall St. âĸ 2026-05-14T10:51:24Z
Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks
Insider Monkey âĸ 2026-05-10T04:01:02Z
Ovid Therapeutics Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-18T21:47:36Z
Here's Why Ovid Therapeutics Stock Popped Higher Today
Motley Fool âĸ 2026-03-18T18:37:42Z
Exchange-Traded Funds, Equity Futures Lower Ahead of Key Economic Data, FOMC Meeting
MT Newswires âĸ 2026-03-18T13:28:29ZOvid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
Zacks âĸ 2026-03-18T11:50:01Z
Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates
Zacks âĸ 2026-03-04T22:35:03Z
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates
Zacks âĸ 2026-02-20T00:00:02Z
Ovid takes another big swing in neuroscience under a new CEO
Pharma Voice âĸ 2026-02-13T08:00:00Z
Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts?
Insider Monkey âĸ 2026-01-30T19:58:30Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $7,252,000 | $566,000 | $392,000 | $1,502,748 |
| Operating Revenue | $7,252,000 | $566,000 | $392,000 | $1,502,748 |
| Expenses | ||||
| Total Expenses | $49,691,000 | $62,451,000 | $59,673,000 | $57,050,399 |
| Other Income Expense | $25,026,000 | $31,500,000 | $2,000,000 | $1,379,132 |
| Other Non Operating Income Expenses | $25,026,000 | $28,200,000 | - | $1,379,132 |
| Operating Expense | $49,691,000 | $62,451,000 | $59,673,000 | $57,050,399 |
| General And Administrative Expense | $24,109,000 | $25,684,000 | $31,085,000 | $32,432,000 |
| Net Non Operating Interest Income Expense | - | $3,900,000 | $4,900,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-17,414,000 | $-26,433,000 | $-52,339,000 | $-54,169,029 |
| Normalized Income | $-17,414,000 | $-29,733,000 | $-54,339,000 | $-54,169,029 |
| Net Income From Continuing And Discontinued Operation | $-17,414,000 | $-26,433,000 | $-52,339,000 | $-54,169,029 |
| Total Operating Income As Reported | $-42,439,000 | $-61,885,000 | $-59,281,000 | $-55,548,161 |
| Net Income Common Stockholders | $-17,414,000 | $-26,433,000 | $-52,339,000 | $-54,169,029 |
| Net Income | $-17,414,000 | $-26,433,000 | $-52,339,000 | $-54,169,029 |
| Net Income Including Noncontrolling Interests | $-17,414,000 | $-26,433,000 | $-52,339,000 | $-54,169,029 |
| Net Income Continuous Operations | $-17,414,000 | $-26,433,000 | $-52,339,000 | $-54,169,029 |
| Pretax Income | $-17,414,000 | $-26,433,000 | $-52,339,000 | $-54,169,029 |
| Operating Income | $-42,439,000 | $-61,885,000 | $-59,281,000 | $-55,547,651 |
| Net Interest Income | - | $3,900,000 | $4,900,000 | - |
| Interest Income | - | $3,900,000 | $4,900,000 | - |
| Interest Income Non Operating | - | $3,900,000 | $4,900,000 | - |
| Per Share | ||||
| Diluted EPS | $-0.23 | $-0.37 | $-0.73 | $-0.77 |
| Basic EPS | $-0.23 | $-0.37 | $-0.73 | $-0.77 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-42,166,000 | $-64,572,000 | $-60,713,000 | $-54,166,045 |
| Reconciled Depreciation | $273,000 | $613,000 | $568,000 | $1,381,606 |
| EBITDA (Bullshit earnings) | $-42,166,000 | $-61,272,000 | $-58,713,000 | $-54,166,045 |
| EBIT | $-42,439,000 | $-61,885,000 | $-59,281,000 | $-55,547,651 |
| Diluted Average Shares | $73,735,606 | $70,905,422 | $70,580,604 | $70,424,819 |
| Basic Average Shares | $73,735,606 | $70,905,422 | $70,580,604 | $70,424,819 |
| Diluted NI Availto Com Stockholders | $-17,414,000 | $-26,433,000 | $-52,339,000 | $-54,169,029 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Research And Development | $25,582,000 | $36,767,000 | $28,588,000 | $24,618,399 |
| Selling General And Administration | $24,109,000 | $25,684,000 | $31,085,000 | $32,432,000 |
| Other Gand A | $14,066,000 | $11,849,000 | $13,954,000 | $16,361,000 |
| Salaries And Wages | $10,043,000 | $13,835,000 | $17,131,000 | $16,071,000 |
| Total Unusual Items | - | $3,300,000 | $2,000,000 | - |
| Total Unusual Items Excluding Goodwill | - | $3,300,000 | $2,000,000 | - |
| Gain On Sale Of Security | - | $3,300,000 | $2,000,000 | - |
| Otherunder Preferred Stock Dividend | - | - | $0 | $0 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $130,660,000 | $68,226,000 | $87,798,000 | $132,050,464 |
| Total Assets | $150,934,000 | $92,167,000 | $144,027,000 | $155,265,814 |
| Total Non Current Assets | $76,566,000 | $36,227,000 | $34,429,000 | $23,885,123 |
| Other Non Current Assets | $1,931,000 | $2,023,000 | $2,141,000 | $1,969,844 |
| Investmentin Financial Assets | $20,812,000 | $0 | - | - |
| Current Assets | $74,368,000 | $55,940,000 | $109,598,000 | $131,380,691 |
| Other Current Assets | $4,733,000 | $2,865,000 | $3,764,000 | $2,379,280 |
| Cash Cash Equivalents And Short Term Investments | $69,635,000 | $53,075,000 | $105,834,000 | $129,001,411 |
| Cash And Cash Equivalents | $13,153,000 | $26,301,000 | $27,042,000 | $44,867,846 |
| Cash Equivalents | $12,636,000 | $25,779,000 | $24,340,000 | $42,014,804 |
| Cash Financial | $516,000 | $522,000 | $2,701,000 | $2,853,042 |
| Goodwill And Other Intangible Assets | - | - | $182,974 | $222,100 |
| Non Current Prepaid Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Receivables | - | - | - | - |
| Debt | ||||
| Total Debt | $13,419,000 | $14,755,000 | $16,002,000 | $16,535,671 |
| Long Term Debt And Capital Lease Obligation | $11,986,000 | $13,419,000 | $14,756,000 | $16,001,725 |
| Current Debt And Capital Lease Obligation | $1,433,000 | $1,336,000 | $1,246,000 | $533,946 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $20,274,000 | $23,941,000 | $56,229,000 | $22,993,250 |
| Total Non Current Liabilities Net Minority Interest | $11,986,000 | $13,419,000 | $44,756,000 | $16,001,725 |
| Current Liabilities | $8,288,000 | $10,522,000 | $11,473,000 | $6,991,525 |
| Payables And Accrued Expenses | $6,855,000 | $9,186,000 | $10,227,000 | $6,457,579 |
| Payables | $1,956,000 | $3,192,000 | $3,703,000 | $1,952,910 |
| Accounts Payable | $1,956,000 | $3,192,000 | $3,703,000 | $1,952,910 |
| Other Non Current Liabilities | - | - | $30,000,000 | - |
| Tradeand Other Payables Non Current | - | - | - | - |
| Non Current Deferred Liabilities | - | - | - | - |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $130,660,000 | $68,226,000 | $87,798,000 | $132,272,563 |
| Total Equity Gross Minority Interest | $130,660,000 | $68,226,000 | $87,798,000 | $132,272,564 |
| Stockholders Equity | $130,660,000 | $68,226,000 | $87,798,000 | $132,272,564 |
| Gains Losses Not Affecting Retained Earnings | $-202,000 | $-35,000 | $1,000 | $-42,187 |
| Other Equity Adjustments | $-202,000 | $-35,000 | $1,000 | $-42,187 |
| Retained Earnings | $-321,713,000 | $-304,299,000 | $-277,865,000 | $-225,526,542 |
| Long Term Equity Investment | $41,961,000 | $20,974,000 | $17,626,000 | $5,622,547 |
| Preferred Stock Equity | - | - | $1 | $1 |
| Other | ||||
| Ordinary Shares Number | $130,184,353 | $71,009,866 | $70,691,992 | $70,466,885 |
| Share Issued | $130,184,353 | $71,009,866 | $70,691,992 | $70,466,885 |
| Tangible Book Value | $130,660,000 | $68,226,000 | $87,798,000 | $132,050,463 |
| Invested Capital | $130,660,000 | $68,226,000 | $87,798,000 | $132,272,563 |
| Working Capital | $66,080,000 | $45,418,000 | $98,125,000 | $124,389,166 |
| Capital Lease Obligations | $13,419,000 | $14,755,000 | $16,002,000 | $16,535,671 |
| Total Capitalization | $130,660,000 | $68,226,000 | $87,798,000 | $132,272,564 |
| Additional Paid In Capital | $452,445,000 | $372,489,000 | $365,591,000 | $357,770,825 |
| Capital Stock | $130,000 | $71,000 | $71,000 | $70,468 |
| Common Stock | $130,000 | $71,000 | $71,000 | $70,467 |
| Preferred Stock | $0 | $0 | $0 | $1 |
| Long Term Capital Lease Obligation | $11,986,000 | $13,419,000 | $14,756,000 | $16,001,725 |
| Current Capital Lease Obligation | $1,433,000 | $1,336,000 | $1,246,000 | $533,946 |
| Current Accrued Expenses | $4,899,000 | $5,994,000 | $6,524,000 | $4,504,669 |
| Investments And Advances | $62,773,000 | $20,974,000 | $17,626,000 | $5,622,547 |
| Available For Sale Securities | $20,812,000 | - | - | - |
| Net PPE | $11,862,000 | $13,230,000 | $14,662,000 | $16,070,632 |
| Accumulated Depreciation | $-1,588,000 | $-1,407,000 | $-1,001,000 | $-581,381 |
| Gross PPE | $13,450,000 | $14,637,000 | $15,663,000 | $16,652,013 |
| Leases | $306,000 | $306,000 | $306,000 | $306,312 |
| Machinery Furniture Equipment | $1,534,000 | $1,534,000 | $1,463,000 | $1,423,032 |
| Buildings And Improvements | $11,610,000 | $12,797,000 | $13,894,000 | $14,922,669 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $56,482,000 | $26,774,000 | $78,792,000 | $84,133,565 |
| Other Properties | - | - | - | $14,922,669 |
| Dueto Related Parties Non Current | - | - | - | - |
| Non Current Deferred Revenue | - | - | - | - |
| Current Deferred Revenue | - | - | - | - |
| Dueto Related Parties Current | - | - | - | - |
| Duefrom Related Parties Current | - | - | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-38,334,000 | $-56,117,000 | $-45,918,000 | $-56,645,903 |
| Operating Activities | ||||
| Operating Cash Flow | $-38,334,000 | $-55,956,000 | $-45,781,000 | $-55,227,127 |
| Cash Flow From Continuing Operating Activities | $-38,334,000 | $-55,957,000 | $-45,781,000 | $-55,227,126 |
| Investing Activities | ||||
| Investing Cash Flow | $-49,854,000 | $54,594,000 | $-2,581,000 | $-87,883,217 |
| Cash Flow From Continuing Investing Activities | $-49,854,000 | $54,593,000 | $-2,580,000 | $-87,883,217 |
| Capital Expenditure | - | $-161,000 | $-137,000 | $-1,418,776 |
| Net Other Investing Changes | - | $1,000 | $-1,000 | $-1,000,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $75,116,000 | $0 | - | - |
| Financing Cash Flow | $75,207,000 | $622,000 | $30,535,000 | $180,658 |
| Cash Flow From Continuing Financing Activities | $75,207,000 | $622,000 | $30,535,000 | $180,658 |
| Net Common Stock Issuance | $75,116,000 | $0 | - | - |
| Common Stock Issuance | $75,116,000 | $0 | - | - |
| Net Other Financing Charges | - | - | $30,000,000 | - |
| Other | ||||
| End Cash Position | $15,084,000 | $28,232,000 | $28,972,000 | $46,798,599 |
| Beginning Cash Position | $28,232,000 | $28,972,000 | $46,799,000 | $189,728,285 |
| Effect Of Exchange Rate Changes | $-167,000 | $0 | - | - |
| Changes In Cash | $-12,981,000 | $-740,000 | $-17,827,000 | $-142,929,686 |
| Proceeds From Stock Option Exercised | $91,000 | $622,000 | $535,000 | $180,658 |
| Net Investment Purchase And Sale | $-49,854,000 | $54,754,000 | $7,557,000 | $-82,964,441 |
| Sale Of Investment | $42,000,000 | $128,000,000 | $120,000,000 | $90,000,000 |
| Purchase Of Investment | $-91,854,000 | $-73,246,000 | $-112,443,000 | $-172,964,441 |
| Net Intangibles Purchase And Sale | $0 | $-90,000 | $-97,000 | $-194,397 |
| Net PPE Purchase And Sale | $0 | $-71,000 | $-40,000 | $-1,224,379 |
| Purchase Of PPE | $0 | $-71,000 | $-40,000 | $-1,224,379 |
| Change In Working Capital | $-4,104,000 | $-150,000 | $2,386,000 | $-8,231,450 |
| Change In Payables And Accrued Expense | $-2,302,000 | $-1,049,000 | $3,771,000 | $-8,340,742 |
| Change In Accrued Expense | $-1,068,000 | $-537,000 | $2,021,000 | $-3,166,606 |
| Change In Payable | $-1,234,000 | $-512,000 | $1,750,000 | $-5,174,136 |
| Change In Account Payable | $-1,234,000 | $-512,000 | $1,750,000 | $-5,174,136 |
| Change In Prepaid Assets | $-1,802,000 | $899,000 | $-1,385,000 | $109,292 |
| Other Non Cash Items | $-844,000 | $-32,913,000 | $-1,678,000 | $-1,219,751 |
| Stock Based Compensation | $4,807,000 | $6,276,000 | $7,285,000 | $6,556,686 |
| Unrealized Gain Loss On Investment Securities | $-21,052,000 | $-3,349,000 | $-2,003,000 | $454,811 |
| Depreciation Amortization Depletion | $273,000 | $613,000 | $568,000 | $1,381,606 |
| Depreciation And Amortization | $273,000 | $613,000 | $568,000 | $1,381,606 |
| Net Income From Continuing Operations | $-17,414,000 | $-26,433,000 | $-52,339,000 | $-54,169,029 |
| Net Business Purchase And Sale | - | $0 | $-10,000,000 | $-2,500,000 |
| Purchase Of Business | - | $0 | $-10,000,000 | $-2,500,000 |
| Amortization Cash Flow | - | - | $148,764 | $193,333 |
| Amortization Of Intangibles | - | - | $148,764 | $193,333 |
| Depreciation | - | - | $1,447,811 | $1,188,273 |
| Purchase Of Intangibles | - | - | - | $-194,397 |
| Change In Receivables | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-06-23